***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: BACKGROUND Furazolidone is a much cheaper drug with a very low resistance against Helicobacter pylori compared to clarithromycin . We aim to evaluate safety and efficacy of a sequential furazolidone-based regimen versus clarithromycin-based therapy in H. pylori eradication for ulcer disease . MATERIAL S Patients with proven peptic ulcer or duodenitis were r and omized into three groups : OAB-M-F ; metronidazole ( M ) ( 500 mg bid ) for the first 5 days , followed by furazolidone ( F ) ( 200 mg bid ) for the second 5 days ; OAC-P ; clarithromycin ( C ) ( 500 mg bid ) for 10 days ; and OAB-C-F ; clarithromycin ( 500 mg bid ) for the first 5 days and furazolidone ( 200 mg bid ) for the second 5 days . All groups received omeprazole ( O ) ( 20 mg bid ) and amoxicillin ( A ) ( 1 g bid ) . Groups OAB-M-F and OAB-C-F were also given bismuth subcitrate ( B ) ( 240 mg bid ) , whereas a placebo ( P ) was given to group OAC-P. Adverse events were scored and recorded . Two months after treatment , a C(13 ) -urea breath test was performed . RESULTS Three hundred and ten patients were enrolled and 92 ( OAB-M-F ) , 95 ( OAC-P ) , and 98 ( OAB-C-F ) completed the study . The intention-to-treat eradication rates were 78.5 % ( 95 % CI = 69 - 85 ) , 81.1 % ( 95 % CI = 73 - 88 ) , and 82 % ( 95 % CI = 74 - 89 ) , and per- protocol eradication rates were 91.3 % ( 95 % CI = 83 - 96 ) , 90.4 % ( 95 % CI = 82 - 95 ) , and 88.7 % ( 95 % CI = 81 - 94 ) , for group OAB-M-F , OAC-P , and OAB-C-F , respectively . Eradication rate differences did not reach statistical significance . The most common adverse event , bad taste , occurred in all groups , but more frequently in groups OAC-P ( 34 % ) and OAB-C-F ( 32 % ) , than OAB-M-F ( 14 % ) ( p < .05 ) . Adverse symptoms score were 0.88 ± 2.05 in group OAB-M-F , 1.15 ± 1.40 in group OAC-P , and 1.87 ± 1.62 in group OAB-C-F. CONCLUSION Furazolidone can replace clarithromycin in H. pylori eradication regimens because of lack of development of resistance and very low cost AIM To compare the efficacy of 14-day and 5-day amoxicillin treatment on the eradication rate during tetracycline containing sequential H. pylori therapy , and also to compare the eradication rate of this regimen with those used in similar studies performed in Turkey . METHOD This study included 112 patients infected with H. pylori that were r and omized into 2 groups . In group A , patients ( n = 56 ) received pantoprazole ( 40 mg BID ) and amoxicillin ( 1 g BID ) for 5 days , followed by pantoprazole ( 40 mg BID ) , tetracycline ( 500 mg QID ) , and metronidazole ( 500 mg TID ) for the remaining 9 days . In group B , patients ( n = 56 ) received pantoprazole ( 40 mg BID ) and amoxicillin ( 1 g BID ) for 5 days , followed by pantoprazole ( 40 mg BID ) , tetracycline ( 500 mg QID ) , metronidazole ( 500 mg TID ) , and amoxicillin ( 1 g BID ) for the remaining 9 days . Eradication rates were calculated using both intention-to-treat ( ITT ) and per- protocol ( PP ) analyses . RESULTS In all , 112 patients were subjected to ITT analysis and 109 patients completed the study . In group A , H. pylori eradication was achieved in 46 ( 82.1 % ) of the 56 patients included in the ITT analysis and in 46 ( 83.6 % ) of the 55 patients included in the PP analysis . In group B , H. pylori eradication was achieved in 44 ( 78.57 % ) of the 56 patients included in the ITT analysis and in 44 ( 81.48 % ) of the 54 patients included in the PP analysis ( Table 2 ) . The eradication rates were not statistically significant between the 2 groups ( p > .005 ) . CONCLUSION Extended duration of amoxicillin treatment during the entire tetracycline containing sequential therapy period did not improve the H. pylori eradication rate . As a consequence , sequential therapy using 5-day amoxicillin is an acceptable first-line therapy option for the eradication of H. pylori in Turkey Abstract Background . Resistance to clarithromycin , a component of st and ard triple therapy , leads to inconsistent eradication rates of Helicobacter pylori  infection  . Some studies have shown higher eradication rates for H. pylori using sequential regimen . This study was done to compare the eradication rates for H. pylori infection between the  st and ard triple drug therapy  and the sequential therapy . Methods . Seventy-three patients with perforated duodenal ulcer following simple closure with H. pylori infection were r and omized to receive either  st and ard triple drug therapy or the sequential therapy . St and ard triple drug therapy comprised of omeprazole , clarithromycin , and amoxicillin for 10 days . Sequential therapy comprised of omeprazole and amoxicillin or the first 5 days followed by omeprazole , clarithromycin , and amoxicillin for the next 5 days . Follow-up endoscopy was done at 2 months to assess the eradication rates , compliance , and side effects with each regimen . Results . Eradication rates for st and ard triple therapy and sequential regimen were 81.25 % and 87.09 % , respectively ( p = 0.732 ) . The cost of sequential therapy was cheaper and incidence of side effects and compliance were similar in each group . Conclusion . St and ard triple therapy and sequential therapy have similar efficacy for eradication of H. pylori and sequential therapy is an economical alternative to st and ard triple therapy BACKGROUND There is an important concern about the success of st and ard triple treatment for  Helicobacter pylori ( H. pylori ) in recent years . Better eradication rates have been reported with sequential treatment in current studies . This study aim ed to compare the success of a novel levofloxacin-containing sequential regimen with st and ard triple therapy . METHODS H. pylori-positive patients with non-ulcer dyspepsia were r and omly allocated to one of the study groups . The patients on sequential arm were given esomeprazole 40 mg BID and amoxicillin 1 g BID for the first week followed by esomeprazole 40 mg BID , levofloxacin 500 mg QD and metronidazole 500 mg TID for the second week . The patients on st and ard triple arm were given esomeprazole 40 mg BID , amoxicillin 1 g BID and clarithromycin 500 mg BID for 2 weeks . Eradication was assessed by urea breath test on 6th weeks . RESULTS Seventy-five patients were enrolled in each group ; 72 in sequential arm and 67 in st and ard arm completed the protocol s. H. pylori eradication rate of per protocol was 90 % in sequential versus 57 % in st and ard treatment groups with a statistical significance ( p<0.000 ) . Both regimens were similarly well tolerated and side effects were comparable . Only one patient in sequential arm stopped the treatment because of side effects . CONCLUSION The levofloxacin-containing sequential therapy is a significantly better strategy than the st and ard triple treatment  for H. pylori eradication .  St and ard triple treatment is no more effective for H. pylori in our population and levofloxacin-containing sequential regimen might be used as a first-line eradication option OBJECTIVES Sequential therapy appears to achieve a higher  Helicobacter pylori eradication rate than triple therapy . We assessed the efficacy and tolerability of modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy . METHODS Patients who failed first-line triple therapy with clarithromycin , amoxicillin and a proton pump inhibitor were eligible in this multicentre trial . Eligible patients were treated with esomeprazole 40 mg and amoxicillin 1 g for the first 5 days , followed by esomeprazole 40 mg , levofloxacin 250 mg and metronidazole 500 mg for another 5 days ( all given twice daily ) . Eradication was confirmed with a (13)C-urea breath test 6 weeks after therapy . Drug susceptibility , presence/absence of gyrA mutation and CYP2C19 genotype were also determined . RESULTS A total of 142 patients were enrolled . The eradication rate was 95.1 % [ 135/142 , 95 % confidence interval ( CI ) 91.5%-98.6 % ] in the intention-to-treat analysis and 96.4 % ( 133/138 , 95 % CI 93.3%-99.5 % ) in the per protocol analysis . Four patients ( 2.8 % ) failed to take at least 80 % of the drugs due to adverse effects . The eradication rates were 50 % ( 4/8 ) and 97.7 % ( 43/44 ) in patients with and without metronidazole resistance , respectively ( P = 0.001 ) . The eradication rates were 84.6 % ( 11/13 ) and 95.1 % ( 58/61 ) in patients with and without gyrA mutation , respectively ( P = 0.210 ) . The eradication rates were not affected by the CYP2C19 polymorphism ( P = 0.421 ) . CONCLUSIONS This modified sequential therapy achieved an excellent eradication rate ( > 95 % ) in second-line treatment and the eradication rate appeared to be affected by metronidazole resistance OBJECTIVE To determine the effectiveness of sequential therapy compared with st and ard triple therapy for Helicobacter pylori eradication in children . STUDY DESIGN In 107 children with H pylori infection confirmed with 2 of 3 tests ( (13)C-urea breath test , histopathology , rapid urease test ) , we conducted a double-blind , r and omized , controlled trial comparing a sequential treatment ( amoxicillin and omeprazole for 5 days followed by clarithromycin , tinidazole , and omeprazole for 5 days ) to a 7-day st and ard triple eradication regimen ( amoxicillin and clarithromycin plus omeprazole ) followed by placebo for 3 days . RESULTS In the experimental group ( n=52 ) compared with the control group ( n=51 ) , there was a significant difference in the H pylori eradication rate at 6 to 8 weeks after the completion of treatment ( primary outcome ) , as confirmed with negative results on (13)C-urea breath test ( 45/52 or 86.5 % versus 35/51 or 68.6 % ; relative risk , 1.26 ; 95 % CI , 1.02 - 1.60 ) . Groups did not differ in any of the secondary outcomes ( ie , adverse effects , the need for discontinuation of the H pylori therapy , compliance with therapy ) . CONCLUSIONS In children with H pylori infection , sequential eradication therapy compared with st and ard triple therapy result ed in a higher eradication rate , although the difference was of borderline statistical significance Background : The prevalence of Helicobacter pylori ( H pylori ) in Turkey is high and eradication rates are low . As a result , alternative treatment strategies are required . Objectives : To evaluate the status of H pylori eradication in Turkey by comparing the results of this study to other studies reported in the literature . Methods : Two hundred and eighty-two patients diagnosed with H pylori were included in this study . Patients were r and omized into two groups . The first group consisted of 138 patients receiving 30 mg lansoprazole bid , amoxicillin 1 g bid , and clarithromycin 500 mg bid for 14 days . The second group consisted of 144 patients who received lansoprazole 30 mg bid and amoxicillin 1 g bid for seven days , followed by metronidazole 500 mg bid , tetracycline 500 mg qid , and lansoprazole 30 mg bid for an additional seven days . Results : H p 
    Output:
    
Both levofloxacin- and tetracycline-based sequential therapies have been proved to be more effective than st and ard triple therapies , confirming that the ' sequential ' administration of drugs is a successful therapeutic procedure for H. pylori infection